)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Vor Biopharma
Vor Biopharma (VOR) investor relations material
Vor Biopharma Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary30 Mar, 2026
Executive summary
Repositioned focus on telitacicept, advancing global Phase 3 trials in generalized myasthenia gravis (gMG) and primary Sjögren's disease (SjD).
First patient dosed in global Phase 3 trial for SjD; topline data for gMG expected in 1H 2027.
$75 million private placement completed to support clinical development.
Financial highlights
Pro-forma cash and investments of $530.2 million as of December 31, 2025, including proceeds from March 2026 private placement, expected to fund operations into early 2029.
R&D expenses for Q4 2025 were $19.2 million, down from $25.3 million in Q4 2024; full-year 2025 R&D expenses rose to $321.5 million from $93.3 million in 2024, mainly due to telitacicept license purchase.
G&A expenses for Q4 2025 were $16.8 million, up from $6.0 million in Q4 2024; full-year 2025 G&A expenses increased to $50.1 million from $27.9 million in 2024.
Net income for Q4 2025 was $1,722.8 million, compared to a $30.7 million net loss in Q4 2024, driven by a gain on change in fair value of liability-classified warrants.
Net loss for full-year 2025 was $696.0 million, compared to $116.9 million in 2024, mainly due to loss on warrant fair value and telitacicept license purchase.
Outlook and guidance
Topline data from the global Phase 3 gMG trial expected in the first half of 2027.
Cash runway projected into early 2029.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Vor Biopharma
- Telitacicept delivers robust, durable efficacy and safety in major autoimmune diseases, enabling global expansion.VOR
Corporate presentation9 Mar 2026 - Telitacicept advances in late-stage trials for MG and Sjögren's, targeting major autoimmune markets.VORTD Cowen 46th Annual Health Care Conference2 Mar 2026
- Gene-edited stem cell transplants for AML show strong early results and pivotal trial progress.VOROppenheimer 35th Annual Healthcare Life Sciences Conference 20253 Feb 2026
- 13.9M shares registered for resale after $150M private placement; no proceeds to the company.VORRegistration Filing29 Jan 2026
- Trem-cel with Mylotarg yields rapid engraftment and promising RFS in high-risk AML.VORStudy Update22 Jan 2026
- Telitacicept advances in global Phase 3 trials for MG and Sjögren's, backed by strong data and funding.VOR44th Annual J.P. Morgan Healthcare Conference16 Jan 2026
- Promising AML trial results, phase III plans, and pipeline growth signal strong momentum.VORStifel 2024 Healthcare Conference13 Jan 2026
- Trem-cel enables rapid engraftment, strong safety, and improved relapse-free survival in AML.VORStatus Update11 Jan 2026
- Registering 125.7M shares post-private placement to fund AML therapy R&D; major investors join board.VORRegistration Filing16 Dec 2025
Next Vor Biopharma earnings date
Q1 202611 May, 2026
Vor Biopharma
Next Vor Biopharma earnings date
Q1 202611 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage